Tofacitinib/Shangjie should not be used for more than a few days at most

Tofacitinib/Shangjie (Tofacitinib), as a small molecule drug targeting the regulation of the JAK pathway, has mature application specifications in the treatment of inflammatory bowel disease and rheumatoid disease. For patients with ulcerative colitis, the guidelines emphasize that “induction therapy needs to last for a sufficient period of time to verify the efficacy.” This also makes patients often ask whether there is a limit on the “maximum number of days of use” of tofacitinib. In fact, unlike emergency drugs, the effect of this drug cannot be judged in a few days, but needs to be evaluated according to a phased plan. For the induction period of adult ulcerative colitis, international recommendations usually require continuous use for at least 8 weeks, and then decide whether to extend to 16 weeks based on symptom improvement to confirm whether the patient has truly entered remission. In other words, tofacitinib does not have a usage limit of "no more than a few days", but is an immunomodulatory drug that is evaluated according to the course of treatment.

Clinical experience shows that the drug’s onset of action is characterized by “early improvement in some patients, while some do not appear until the third to fourth weeks.” Therefore, premature discontinuation may lead to insufficient treatment. After the induction phase, if the patient achieves significant control, many guidelines recommend entering a maintenance phase to reduce the risk of relapse. Unlike drugs that require precise control of the duration of use on a daily basis, tofacitinib emphasizes observing response, monitoring safety and maintaining the treatment plan on a periodic basis under the guidance of a professional physician. Since its mechanism of action involves the regulation of the JAK-STAT pathway, it is necessary to pay attention to the risk of infection, blood lipid changes and some laboratory indicators during treatment. Overseas experts therefore recommend "stable treatment time + regular safety monitoring" as the core of use.

Generally speaking, there is no "maximum number of days" limit for tofacitinib. Instead, the efficacy is evaluated according to the induction logic of 8-16 weeks, and then a longer period of maintenance treatment is entered according to the type of disease. Therefore, patients should focus on the treatment plan rather than the limit on the number of days to ensure stable benefits under professional follow-up.

Reference materials: https://www.xeljanz.com/